HeartSciences Inc. logo

HeartSciences Inc.(HSCS)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$2.12
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for HSCS

11/13/2026: HSCS (1-star) is currently NOT-A-BUY. Pass it for now.

HeartSciences Inc. is a micro-cap medical technology company focused on enhancing electrocardiography through artificial intelligence and cloud-based software solutions. The company's main strengths lie in its proprietary AI-ECG algorithms, FDA clearances, and clinical validation partnerships with leading academic medical centers. Its core investment story centers on the commercial potential of its MyoVista wavECG hardware and vendor-agnostic MyoVista Insights platform to revolutionize early cardiac screening. However, the company faces severe financial risks, including negligible commercial revenue, recurring operational losses, and going-concern warnings that threaten balance sheet stability. This stock best suits high-risk speculative investors willing to monitor ongoing liquidity developments, regulatory progress, and strategic corporate transactions.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitThe company lacks the commercial revenue scale and consistent top-line growth required for a traditional growth investment style.
Momentum investorStrong fit while signal remains positiveMicro-cap clinical technology stocks can occasionally experience sharp, sentiment-driven momentum spikes around regulatory announcements or corporate transactions.
Value investorWeak fit Ongoing operational losses, negative equity, and going-concern uncertainties render traditional value metrics unsupportable.
Dividend investorWeak fitThe company does not pay dividends and retains all capital to fund ongoing research and operations.
Low-risk investorWeak fitHigh share price volatility, capital dilution risk, and balance sheet distress present substantial risk for conservative investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighLow trading float and micro-cap status result in sharp daily price swings.
Valuation riskHighValuation is heavily speculative due to negligible current revenue and heavy dilution risk.
Competition risk (AI-enabled medical device competition)HighWell-capitalized healthcare giants are rapidly integrating proprietary AI capabilities into standard diagnostic hardware.
Business qualityMedium / highInnovative core technology is counterbalanced by early-stage commercialization hurdles and financial distress.
Dividend incomeLow / noneThe company provides no dividend yield or income generation for shareholders.
Execution riskHighTranslating regulatory clearances and software integrations into sustainable commercial revenue remains a formidable challenge.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 10.56M USD
Price to earnings Ratio -
1Y Target Price 12
Price to earnings Ratio -
1Y Target Price 12
Volume (30-day avg) 179.6K shares
Beta 1.81
52 Weeks Range 1.63 - 5.25
Updated Date 11/15/2026
52 Weeks Range 1.63 - 5.25
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -3.21

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -45.22%
Avg. Invested days 14
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
HSCS receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft company fundamentals, and soft quantitative characteristics.

Company Fundamentals

★★★★★
HSCS has soft overall fundamentals (2 stars), with weak financial health, moderate growth momentum, and solid ownership. In FY2026 versus FY2025, growth and ownership metrics are mixed: slightly negative earnings growth (-4.3%), weak cash generation (FCF margin -172983.5%), slightly negative revenue growth (-0.7%).

Financial Health Rating

★★★★★
HSCS's financial health is weak, with the relatively strongest area being soft cash strength, including free-cash-flow generation (-172983.5% of revenue). Operating efficiency is weak (1 stars), which helps explain the 1-star overall score.

Growth Momentum Score

★★★★★
HSCS's growth profile is soft, with the least-weak measure being free-cash-flow growth at -0.4% FY2026 versus FY2025. By comparison, while revenue growth (-0.7%, slightly negative) and earnings growth (-4.3%, slightly negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 4.4% and approximately 68.3% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 19.98% supports management-shareholder alignment.

Top 5 Institutional Investors

TFB Advisors LLC 0.60%
Geode Capital Management, LLC 0.46%
Vanguard Capital Management, LLC 0.36%
Vanguard Fiduciary Trust Co 0.35%
Tradition Wealth Management LLC 0.34%

Unit Economics (Per $1K Revenue)

★★★★★
HSCS generates approximately $-29,821 of gross profit, $-1,947,874 of operating income, and $-1,729,835 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 40.29%

Quantitative Style Profile

★★★★★
HSCS has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Diagnostic Hardware & Software LicensingPlanned sales of MyoVista wavECG devices and SaaS licensing or usage fees from the MyoVista Insights cloud platform.The company currently generates negligible revenue and is pre-commercial in scaling its intended software and hardware revenue streams.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 14.56M
Price to Sales(TTM) 2336.74
Enterprise Value 14.56M
Price to Sales(TTM) 2336.74
Enterprise Value to Revenue 3221.95
Enterprise Value to EBITDA -0.14
Shares Outstanding 4.97M
Shares Floating 3.39M
Shares Outstanding 4.97M
Shares Floating 3.39M
Percent Insiders 19.98
Percent Institutions 4.4

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.